» Articles » PMID: 18319306

Metformin Treatment for Four Years to Reduce Total and Visceral Fat in Low Birth Weight Girls with Precocious Pubarche

Overview
Specialty Endocrinology
Date 2008 Mar 6
PMID 18319306
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Context And Objective: A low birth weight (LBW) tends to be followed by overweight due to an excess of fat, including visceral fat. LBW girls with precocious pubarche (PP) (pubic hair < 8 yr) are at high risk for developing an adipose state of hyperinsulinemic androgen excess that leads toward early menarche. We explored the effects of insulin sensitization with metformin in LBW-PP girls. SETTING, DESIGN, PATIENTS, INTERVENTION: Prepubertal LBW girls with PP (mean body weight 2.4 kg; age 7.9 yr; body mass index 18.4 kg/m(2)) were studied. Girls were randomly assigned to remain untreated (n=19) or receive metformin for 4 yr (n = 19; 425 mg/d for 2 yr, then 850 mg/d for 2 yr).

Main Outcomes: At the start and after 4 yr, height, weight, fasting insulin, glucose, IGF-I, testosterone, lipids, leptin, high molecular weight adiponectin, body composition by absorptiometry, abdominal fat partitioning (only 4 yr) by magnetic resonance imaging, and menarcheal status were determined.

Results: Metformin-treated girls gained on average 5.5 kg (or approximately 50%) less fat, after 4 yr were less insulin resistant and less hyperandrogenic, had lower IGF-I levels and a less atherogenic lipid profile, and were less likely to be post-menarcheal than untreated girls, whereas their gain in height, lean mass, and bone mineral density were similar. After 4 yr, untreated girls had more visceral fat, a higher ratio of visceral-to-sc fat, and a higher leptin-to-high molecular weight adiponectin ratio (all approximately 50% higher) than metformin-treated girls.

Conclusion: Long-term metformin treatment appears to reduce total and visceral fat in LBW-PP girls, and to delay menarche without attenuating linear growth, thereby opening the perspective that adult height may be increased.

Citing Articles

Ciliopathies are responsible for short stature and insulin resistance: A systematic review of this clinical association regarding SOFT syndrome.

Perge K, Capel E, Senee V, Julier C, Vigouroux C, Nicolino M Rev Endocr Metab Disord. 2024; 25(5):827-838.

PMID: 39017987 PMC: 11470920. DOI: 10.1007/s11154-024-09894-w.


Metformin treatment of juvenile mice alters aging-related developmental and metabolic phenotypes in sex-dependent and sex-independent manners.

Zhu Y, Engmann M, Medina D, Han X, Das P, Bartke A Geroscience. 2024; 46(3):3197-3218.

PMID: 38227136 PMC: 11009201. DOI: 10.1007/s11357-024-01067-6.


Effects of metformin on bone mineral density and bone turnover markers: a systematic review and meta-analysis.

Hu J, Han J, Jin M, Jin J, Zhu J BMJ Open. 2023; 13(6):e072904.

PMID: 37355276 PMC: 10314630. DOI: 10.1136/bmjopen-2023-072904.


Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol.

Bassols J, de Zegher F, Diaz M, Carreras-Badosa G, Garcia-Beltran C, Puerto-Carranza E Trials. 2023; 24(1):56.

PMID: 36694227 PMC: 9873221. DOI: 10.1186/s13063-022-07050-w.


Highlighting the trajectory from intrauterine growth restriction to future obesity.

Gantenbein K, Kanaka-Gantenbein C Front Endocrinol (Lausanne). 2022; 13:1041718.

PMID: 36440208 PMC: 9691665. DOI: 10.3389/fendo.2022.1041718.